California Snaps Up Civica For Biosimilar Insulin Initiative
Plus Brand Insulins Drop Prices Following Landmark Lilly Decision
Civica is set to provide biosimilar insulins to the state of California through its CalRx program, following approval from the US Food and Drug Administration.
